Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults

计划入组 31 人 · 首次发布于 2010 年 12 月 24 日

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

计划入组 242 人 · 首次发布于 2023 年 1 月 17 日

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

计划入组 35 人 · 首次发布于 2016 年 8 月 4 日

5-HT 6 antagonists (MANTRA, CIAS)

KYN-5356

CIAC-001

GCS CIPS

France

CHAS MARIE

France

CIS BIO INTERNATIONAL

France

Atai Life Sciences' Schizophrenia Cognitive Drug Inidascamine Fails Primary Endpoint in Phase 2 Trial

Kynexis Extends Series A to €97 Million to Advance First-in-Class KAT-II Inhibitor for Cognitive Impairment in Schizophrenia

Two Phase 2 Trials Fail to Demonstrate Cognitive Benefits in Schizophrenia Despite Different Mechanisms